Michael Giovingo, MD
Glaucoma Specialist · Boston, MANPI 1962668624
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. Iridex Corporation accounts for 76.1% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2022 at $6,196 and has fallen 69.5% since, to $1,891 in 2025.
Across 92 payments — averaging $239.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Iridex Corporation$17K
- NEW World Medical,inc.$1K
- Glaukos Corporation$1K
- Alcon$924
- Sight Sciences, Inc.$809
- AbbVie$256
- plus $731 from 10 others
What the payments were for
- Consulting fees$5,00023%
- Speaking & faculty fees$11,75053%
- Food & beverage$5,31524%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Iridex Corporation | 11 | $16,791 |
| NEW World Medical,inc. | 16 | $1,322 |
| Glaukos Corporation | 15 | $1,232 |
| Alcon | 15 | $924 |
| Sight Sciences, Inc. | 13 | $809 |
| AbbVie(2 entities) | 4 | $256 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $170 |
| Amgen | 5 | $169 |
| Nova Eye, Inc. | 1 | $95 |
| Genentech, Inc. | 1 | $88 |
| Bausch & Lomb Americas Inc. | 2 | $75 |
| Ivantis, Inc | 1 | $43 |
| Novartis | 1 | $28 |
| Aerie Pharmaceuticals, Inc. | 1 | $25 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $21 |
| Ocular Therapeutix, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ahmed Glaucoma Valve$872
- Kahook Dual Blade$872
- Clearpath$492
- Streamline$492
- OMNI(R) SURGICAL SYSTEM (US)$426
- Via360$285
- SION SURGICAL INSTRUMENT$282
- Hydrus Microstent$275
- Streamline Surgical System$262
- AcrySof$251
- iDoseTR$211
- iStent inject W$163
- XEN GLAUCOMA TREATMENT SYSTEM$150
- AcrySof IQ VIVITY IOL$145
- iDose$120
- ENVISTA$113
- iStent Trabecular Micro-Bypass System Model iS3$108
- TEPEZZA$105
- OMNI$101
How this compares
Too few glaucoma specialist providers in Massachusettsto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 44 | $13,961 |
| Brinzolamide | 28 | $4,220 |
| Travoprost | 17 | $3,542 |
| Dorzolamide Hcl | 239 | $3,322 |
| Latanoprost | 380 | $2,046 |
| Timolol Maleate | 212 | $1,851 |
| Brimonidine Tartrate | 188 | $1,782 |
| Levobunolol Hcl | 34 | $1,193 |
| Prednisolone Acetate | 11 | $442 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 27 | $184 |
| Acetazolamide | 11 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa | $25 | $13,96144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Massachusettson file to place this against a meaningful peer group, so we don't.
Other glaucoma specialist in Boston
- Cynthia MattoxBoston$91K
- Sarwat SalimBoston$83K
- Aseef AhmedBoston$5K
- Michelle HuynhBoston$2K
- Courtney OndeckBoston$789
- Deidrya JacksonBoston$511
- Chandrasekharan KrishnanBoston$223
- Susan LiangTaunton$3K
- Isha IngleWorcester$2K
- Nathalie RiouxGreenfield$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.